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Abstract
Epidemiological, preclinical and clinical studies demonstrated that chronic inflammation induced by hepatitis C
virus (HCV) is crucial in hepatocellular carcinogenesis. The interaction between hepatocytes and microenvironment
regards virus, inflammatory and immunocompetent cells, chemo- and cyto-kines, reactive oxygen species (ROS)
and nitric oxide (NO), generating cell transformation. We suggest hepatocarcinoma (HCC) as a model in which the
targeting of microenvironment determine neoplastic transformation. The present review focuses on: the role of
inflammation in carcinogenesis, the clinical impact of HCC and the inadequacy of the actual therapy, the chemo-
prevention targeting the microenvironment.
HCC epidemiology
Hepatocellular carcinoma (HCC) accounts for > 5% of all
human cancers and for 80% - 90% of primary liver can-
cer. It is a major health problem worldwide being the
fifth most common malignancy in men and the eighth in
women; the third most common cause of cancer-related
death in the world. Moreover early diagnosis is uncom-
mom and medical treatments are inadeguate [1].
Yearly 550,000 people worldwide die for HCC, with a
2:1 ratio for men versus women. Its incidence is increas-
ing dramatically, with marked variations among geo-
graphic areas [2], racial and ethnic groups, environmental
risk factors [3,4]. The estimated annual number of HCC
cases exceeds 700,000, with a mean annual incidence of
3-4% [2]. Most HCC cases (> 80%) occur in either sub-
Saharan Africa or in Eastern Asia (China alone accounts
for more than 50% of the world’s cases) [2]. In the United
States (US) HCC incidence is lower than other countries
(0.3/100,000) even if there has been a significant and
alarming increase in the incidence of HCC in the US,
from 1.3 in the late 70s’ to 3 in the late 90s’, due to HCV
infection. In 2008, 21,370 new cases of HCC and intrahe-
patic bile duct cancer were estimated with 18,410 deaths
[2]. In Europe, Oceania and America, chronic hepatitis C
and alcoholic cirrhosis are the main risk factors for HCC.
The main risk factor for HCC development in patients
with hepatitis C is the presence of cirrhosis. Among
patients with hepatitis C and cirrhosis, the annual inci-
dence rate of HCC ranges between 1-8%, being higher in
Japan (4-8%) intermediate in Italy (2-4%) and lower in
USA (1.4%) [5]. Analysis of mortality from HCC in Eur-
ope confirmed large variability, with high rates in France
(6.79/100,000) and Italy (6.72/100,000) due to hepatitis C
virus (HCV) during the 1960 s and 1970 s [6]. Southern
Italy has the highest rates of HCC in Europe [7].
HCC etiopatogenesis
HCC is unique among cancers occurring mostly in
patients with a known risk factor: ninety percent of
HCCs develop in the context of chronic liver inflamma-
tion and cirrhosis [1]. Hepatitis B (HBV) and C (HCV)
viruses are the major cause of liver disease worldwide.
Fortunately, the hepatitis B virus vaccine has resulted in
a substantial decline in the number of new cases of
acute hepatitis B among children, adolescents, and
adults in western countries since the mid-1980 s. This
success is not duplicable for HCV where active or pas-
sive vaccination is not available yet. Therefore, the pre-
sent and next future HCC history will be mainly related
to HCV infection. The incidence of HCV infection is
hard to quantify since it is often asymptomatic. The
World Health Organization estimates that 3% of the
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chronically infected (3-4 million new infections every
year). Therefore, a tremendous number of people are
currently at elevated risk for HCC and its early diagnosis
(when surgical intervention is possible) may significantly
affect the patients prognosis [8].
However it is possible also a direct carcinogenesis by
hepatitis viruses, without a cirrhotic step [5,9]. In parti-
cular, it was reported that patients without cirrhosis
were younger, survived longer than patients with cirrho-
sis (P < 0.0001) and had a better 5-year survival experi-
ence [10]. The action of some viral proteins (mainly the
HCV core protein and the HBV X protein) [11] or
insertional mutagenesis in the case of HBV [12,13] were
suggested as potential mechanisms to induce HCC.
In contrast to HBV, HCV does not integrate into the
host genome and does not contain a reverse transcrip-
tase. In particular, in the infected subjects both viruses
trigger an immune-mediated inflammatory response
(hepatitis) that either clears the infection or slowly
destroys the liver [14].
Effective HCV immunity is limited by the high variabil-
ity of virion genome; HCV virions turn over rapidly (with
a half-life of about 3 h), and up to about 10
12 complete
viruses are produced per day in an infected person [15].
About 80% of newly infected patients develop chronic
infection; an estimated 10% to 20% will develop cirrhosis
and 1-5% proceeds to end-stage liver cancer over a per-
iod of 20 to 30 years (Figure 1). In the case of HCV, HCC
is invariably observed as a complication of cirrhosis,
whereas in the case of HBV HCC is often found in non-
cirrhotic liver. Therefore, the hepatic fibrosis dramatically
increases the incidence of HCC [16].
Anti-HCV immune response
Innate response
In the blood of infected patients, HCV is associated with
blood lipoprotein VLDL, LDL, and HDL; although the
virus binds to different molecules it requires tetraspanin
CD81, the scavenger receptor class B type I (SR-BI), the
tight junction proteins claudin (CLDN1) and occludin
[17-20] to entry into hepatocytes. The host response is
triggered when a pathogen-associated molecular pattern
(PAMP), presented by the infecting virus, is recognized
and engaged by specific pathogen recognized receptor
(PRR), as the Toll-like receptors (TLRs) [20,21]. Early
after infection, the immune system reacts to viral RNA
through a signaling cascade which results in interferon
(IFN) production [22].
Two main pathways lead to an IFN response. One is
mediated by retinoic acid inducible gene-I (RIG-I) reti-
noic acid/MDA5 while MyD88 (myeloid differentiation
primary response gene 88) activates the other. RIG-1
senses triphosphorylated single stranded HCV RNA and
MDA5 recognizes dsRNA. Both act on Interferon pro-
moter stimulator 1(IPS-1) that transmits the activation
signal to IKKe and TANK-binding kinase-1 (TBK-1).
These two kinases in turn phosphorylate the interferon
regulator factor-3 (IRF-3) that activates the IFN-b pro-
moter [23].
Double-stranded HCV RNA is also recognized by
TLR-3, which activates IKKe/TBK-1, via TRIF (TIR-
domain-containing adapter-inducing interferon-b)j o i n -
ing the RIG-I/MDA5 pathway. In the other pathway,
TLR7 senses single-strand HCV RNA and via the
MyD88 adaptor protein activates IRAK4/IRAK1. These
kinases stimulate IFN-c synthesis via the transcription
factor of interferon response factor 7. MyD88 is a uni-
versal adaptor protein being used by other TLRs (except
TLR-3) to activate the transcription factor NF-kB. This
leads to the expression of IFN-a/b, other cytokines/che-
mokines and facilitates leucocyte recruitment. Secreted
IFN-a/b bind to IFN receptors to stimulate the Jak-
STAT pathway, resulting in the induction of over 300
genes. Several IFN-induced proteins (the protein kinase
R, the RNAspecific adenosine deaminase 1, the 2’-5’ oli-
goadenylate synthetases (2-5 OAS)/RNaseL system53
and P56) were reported to have anti-HCV activities.
HCV strategies to evade IFN mediated response
HCV evades INF-mediated antiviral activity using sev-
eral different strategies [23]. A classic example of a
PAMP is double stranded RNA and the best-described
PRRs in hepatocytes are RIG-1 and TLR3, a toll-like
receptor. When these PRRs detect viral invaders, such
as HCV, they trigger signaling cascades that result in
the transcription of IFNs and key messenger cytokines
that activate host defenses. RIG-1 is activated by the
binding of viral RNA, which enables RIG-1 to bind to
IFN promoter stimulator 1(IPS-1) and trigger a signal-
ing cascade that results in IFN transcription. IPS-1 is
normally localized to the membranes of mitochondria
but the HCV NS3-4a protease cleaves IPS-1, which
causes it to delocalize from the mitochondrial mem-
brane and prevents RIG-1 signaling. Importantly, liver-
tissue samples from patients infected with HCV
demonstrate IPS-1 delocalization, which suggests that
this mechanism is clinically relevant. NS3-4a has also
been demonstrated to inactivate the cellular protein
toll-interleukin-1 receptor domain-containing adaptor
inducing IFN (TRIF). TRIF is an adaptor protein that
is a critical component of the TLR3 signaling pathway.
By cleaving IPS-1 and inactivating TRIF, HCV disrupts
the ability of a cell to detect its presence, as a conse-
quence, IFN production is diminished and host
defenses are impaired [23].
H C Vi sa l s oa b l et oi n t e r f e r ew i t hs p e c i f i ch o s t
defenses that are induced by IFNs. The cellular factor
PKR shuts down the production of proteins in infected
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cells from being used as factories for virus production.
The ability of NS5a to inhibit PKR seems to be HCV-
genotype specific and could be one reason for the
greater sustained viral response (SVR) rate observed in
patients infected with genotype 2 than in those with
other HCV genotypes [24].
Natural Killer cells
HCV again employs multiple mechanisms to escape the
NK cell response. Dysfunctional NK cells were found
both in the periphery and in the liver during HCV infec-
tion. First, HCV E2 binding to CD81 directly inhibited
NK cell activity. Second, HCV core protein stabilized
the HLA-E expression and inhibited cytolysis of NK
cells. Third, the transforming growth factor b (TGF-b)
upregulates the inhibitory dimer of CD94/NKG2A on
NK cells in HCV-infected patients. In addition, dendritic
cells (DC) sense virus infection via toll-like receptors
(TLR) or retinoic acid inducible gene-I (RIG-I), resulting
in the secretion of type-I interferons (IFN) and inflam-
matory cytokines. In Myeloid DC from HCV-infected
patients the levels of TLR/RIG-I-mediated IFN-b or
TNF-a induction are lower than those in uninfected
donors. These results suggest that the signal transduc-
tion in the downstream of TLR/RIG-I in MDC is
profoundly impaired in HCV infection. In response to
IFN-a, DC are able to express MHC class-I related
chain A/B (MICA/B) and activate natural killer (NK)
cells following ligation of NKG2 D. Interestingly, DC
from HCV-infected patients are unresponsive to exogen-
ous IFN-a to enhance MICA/B expression and fail to
activate NK cells [25].
Furthermore, modulation of TLR-mediated signaling
in a macrophage cell line expressing HCV proteins was
identified. Clinical trials showed that agonists of TLR3,
TLR4, TLR7, TLR8, and TLR9 were potent inducers of
antiviral activity. These data indicate that stimulation of
certain TLRs may have benefit on restoration of innate
and adaptive immunity in chronic HCV infection.
Therefore, cross talks between DC, NK, and NKT cells
are critical in shaping subsequent adaptive immune
response against HCV.
Plasmacytoid dendritic cells (PDCs)
Interestingly, patients who are chronically infected with
HCV have decreased numbers of PDCs compared with
healthy controls. Furthermore, PDCs from HCV-infected
Figure 1 Evolution from HCV infection to HCC.
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PDCs from healthy individuals [23]. In HCV-infected liver
the plasmacytoid dendritic are responsible for the produc-
tion of interferon I (IFN-I) binding to the IFN-a/b recep-
tor activates the JAK/STAT pathway, which results in the
induction of IFN-stimulated genes (ISGs) [26].
Host factors are involved in innate immune response.
Certain human leukocyte antigen (HLA) allelic variants
of DRB1 and DQB1 are associated with spontaneous
HCV clearance, being polymorphisms in the interleukin
(IL)-12B gene. Three landmark genome-wide association
studies (GWAS) recently identified IL-28B gene locus is
pivotal to the pathogenesis of HCV infection. Poly-
morphisms near the IL-28B gene not only predicted
treatment-induced and spontaneous recovery from HCV
infection, but they also explained, to some extent, the
difference in response rates between Caucasians and
African Americans to standard therapy with pegylated
interferon and ribavirin [27].
Specific immunity
Immature dendritic cells (iDCs) present in the liver
express low levels of MHC class II and co-stimulatory
molecules (CD80 and CD86), lacking CD1a, producing
suppressive cytokines such as interleukin 10 (IL-10)
[28]. Mature DCs (mDC) release a variety of cytokines
(IL-12, TNF-a,I L - 1 8 ,o rI F N - a) that act on NK cells,
mDCs prime TH0 cells and induce inflammatory CD4+
T-helper type 1 (TH1) cells and CD8+ CTL responses.
Antigen-specific TH1c e l l sp r o d u c eI L - 2a n dI F N - g.
IL-2-activated NK cells kill iDCs, thus limiting (down-
regulating) the immune response. Impairment of DCs in
NK cell activation may be responsible for the failure of
an adequate immune response against HCV in the early
phase of primary HCV infection [29,30] through secre-
tion of suppressive cytokines IL-10 and TGF-b1[ 3 1 - 3 3 ]
as well as insufficient production of IFN-g by NK cells
in response to IL-12 and IL-15 activation [34]. A signifi-
cant proportion of hepatic T cells are either CD4+ or
double negative (CD4-CD8-) and express receptors typi-
cal of both NK cells (CD16+, CD56+, CD161+) and T-
cells (T-cells receptors, TCRs). These cells, called NKT,
constitute a conserved T-cell sublineage with unique
properties; NKT cells express a limited abTCR reper-
toire (i.e. an invariant V24-J15 TCR) and recognize gly-
colipid antigens presented by CD1 d molecules. On
activation, NKT cells rapidly produce large amount of
IFN-g, a major cytokine of TH1 immune responses that
inhibits HCV replication through a noncytolytic
mechanism [35-37], or IL-4 and IL-13, the major cyto-
kines of TH2 responses [38]. NKT cells are a link
between innate and adaptive immunity exerting strong
regulatory activity and producing profibrotic cytokines
(IL-4 and IL-13) crucial for cirrhosis progression [38,39].
Both HCV-specific IFN-g-producing CD8+ T cell
response and a strong proliferative CD4+ T-cell
response are generated during the first 6 months after
infection [30,40,41]. A persistent CTL activity has been
detected in patients in which HCV infection was cured
but not in patients with chronic HCV infection, indicat-
ing that the CTL response has a key role in the clear-
ance of the virus [42,43].
Immunoregolatory cells
Much attention has recently focused on regulatory T
cells (Tregs) being able to secrete inhibitory cytokines
such as IL-10 or TGF-b [44], even if their contribution
is yet unclear [4]. Increased Treg cells were found in per-
ipheral blood of HCV-infected patients [45-47] as well
as in the tumor microenvironment of HCC patients
[48]. The frequency of naturally arising CD4
+CD25
high+
Tregs in the periphery of HCV-infected patients was
reported to be higher than that in patients who resolved
the infection or uninfected controls [46]. TH1 cytokines
are generally up-regulated in patients with HCC, result-
ing in higher levels of pro-inflammatory cytokines, as
IL-1b,I L - 1 5 ,I L - 1 8 ,T N F - a,T N F - aRs, TNF-aRI, TNF-
aRII, and IL-6 in comparison with healthy individuals
[49]. However, the intra/peri-tumoral cytokines levels
are often different from the serum levels [50]. Higher
serum IL-6 level was an independent risk factor for
HCC development in female but not male chronic hepa-
titis C patients [51]. IL-10 was highly expressed in HCC
tumors and serum, correlating with disease progression
[50]. Budhu and Wang reviewed the association between
cytokine abnormalities and HCC patients and found that
ad o m i n a n tT H2-like cytokine profile (IL-4, IL-8, IL-10,
and IL-5) and a decrease in the TH1-like cytokines (IL-
1a,I L - 1 b, IL-2, IL-12p35, IL-12p40, IL-15, TNF-a,a n d
IFN-g,) was associated with the metastatic phenotype of
disease [50]. Thus, it has been hypothesized that TH1
cytokines are involved in tumor development, whereas
TH2 cytokines in tumor progression. Preliminary data
showed that pro-inflammatory molecules (IL-1a,I L - 6 ,
IL-8, IL-12p40, GM-CSF, CCL27, CXCL1, CXCL9,
CXCL10, CXCL12, b-NGF) resulted significantly up-
regulated in patients affected by HCC with chronic
HCV-related hepatitis and liver cirrhosis [52].
Chronic inflammation and systemic oxidative
stress
The network linking HCV infection, inflammation, free
radical production, and carcinogenesis is clearly detect-
able in HCV-mediated chronic liver damage [53].
The main sources of reactive species in cells are mito-
chondria, cytochrome P450 and peroxisome. Under phy-
siological conditions, there is a constant endogenous
production of reactive oxygen and nitrogen species
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for metabolism, cell cycle and intercellular transduction
pathways [54]. To control the balance between produc-
tion and removal of ROS, as hydroxyl and superoxide
radicals, and RNS, as nitric oxide (NO), peroxynitrite
and S-nitrosothiols, there are a series of protective
molecules and systems globally defined as ‘’antioxidant
defences’’. Oxidative stress occurs when the generation
of free radicals and active intermediates in a system
exceeds the system’s ability to neutralize and eliminate
them. In these conditions, ROS and RNS affect the
intracellular and intercellular homeostasis, leading to
possible cell death and regeneration. Among ROS, the
hydroxyl radical is the most damaging radical (Figure 2).
It is involved in lipid peroxidation, DNA and protein
oxidation and induces cell membrane damage, gene
mutations, gene damage implicated in cell growth, cell-
cycle, apoptosis, increase of 4-hydroxynonenal and
8-hydroxydeoxyguanosine, disruption of DNA repair
pathways.
In the case of liver chronically infected by HCV [55]
the virus induces reactive oxygen species (ROS) [56],
and compromise the repair of damaged DNA, rendering
cells more susceptible to spontaneous or mutagen-
induced alterations, the underlying cause of liver cirrho-
sis and hepatocellular carcinoma [56]. Therefore, free
radical production, oxidative genomic injury, constitutes
the first step of a cascade of epigenetic (aberrant DNA
methylation), genomic (point mutations) and post-geno-
mic (protein oxidation and cytokine synthesis) events
that lead to HCC [57-59]. Initially ROS interact directly
with DNA, damaging specific genes that control cell
growth and differentiation, cell-cycle, apoptosis, lipid
peroxidation, and DNA damage repair [60]. Moreover,
patients infected with HCV show increase in lipid per-
oxidation levels [61,62], 4-hydroxynonenal and 8-hydro-
xydeoxyguanosine [63-65]. Increased levels of ROS/RNS
are associated with decreased antioxidant levels [63,64].
Therefore, the increased generation of reactive oxygen
and nitrogen species, together with the decreased anti-
oxidant defense, promote the development and progres-
sion of hepatic and extrahepatic complications of HCV
infection [66].
Interestingly, the presence of ROS and RNS is higher
in patients infected with HCV than HBV. ROS play also
an important role in fibrogenesis throughout increasing
platelet-derived growth factor [56] or the secretion
of profibrotic cytokines, such as TGF-b. A recent
Figure 2 Reactive oxygen species. Cells generate aerobic energy by reducing molecular oxygen (O2) to water. During the metabolism of
oxygen, superoxide anion (
.O2) is formed in presence of NADPH P450 reductase. After superoxide dismutase (SOD) is added to the system,
superoxide undergoes dismutation to hydrogen peroxide (H2O2), which is converted by glutathione peroxidase or catalase to water. MPD
(myeloperoxidase) converts H2O2 in neutrophils to hypochlorous acid (HOCl), a strong oxidant that acts as a bactericidal agent in phagocytic
cells. During a Fenton reaction, Fe
2+ is oxided to Fe
3+ and H2O2 is converted in the highly reactive hydroxyl radical ·OH. This radical is involved
in lipid peroxidation, DNA and protein oxidation.
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patients at different stages of fibrosis revealed a correla-
tion between the down-regulation of antioxidant pro-
teins and the later stages of liver fibrosis, consistent
with a role of oxidative stress in the progression of liver
fibrosis and cirrhosis [67,68].
Current HCC treatment
Surgery
Despite surgery or liver transplant can successfully cure
small or slow-growing tumors, few therapeutic options
are available for advanced disease with negligible clinical
benefit. For HCV-related HCC the curative therapy is
surgery, either hepatic resection or liver transplantation;
patients with single small HCC (< 5 cm) or up to three
lesions < 3 cm should be referred for these treatment.
Only 10-20% of HCC patients are candidates for surgery
because of tumor size, multifocality, vascular invasion,
or hepatic functional failure. In addition for patients
resected, the recurrence rate can be as high as 50%[1].
Although liver transplantation has been successful for
the treatment of early-stage liver cancer, a small number
of HCC patients qualifies for transplantation due to
donor organ shortage as well as the rapid and frequent
recurrence of HCC in the transplanted liver.
Systemic Therapy
At present, there is no effective systemic chemotherapy
for HCC. Sorafenib, a vascular endothelial growth factor
receptor tyrosine kinase inhibitor, has been approved by
the United States Food and Drug Administration for the
treatment of unresectable HCC; recent studies indicate
that it is able to prolong the median survival time by
nearly three months in patients with advanced HCC
[1,2], but severe adverse effects, including a significant
risk of bleeding, compromised these results [3].
Alternative treatment modalities
Alternative treatment modalities including transcatheter
arterial chemoembolization, targeted intra-arterial deliv-
ery of Yttrium-90 microspheres, percutaneous intratu-
mor ethanol injection, and radiofrequency ablation are
primarily for palliation and are applicable only to
patients with localized liver tumors [69].
Antioxidants role in HCC chemoprevention
In view of the limited treatment and poor prognosis of
liver cancer, preventive approaches, notably surveillance
and chemoprevention, have to be considered as the best
strategies in lowering the current morbidity and mortal-
ity associated with HCC [15]. Given the strong associa-
tion between etiologic agents, chronic liver disease
(hepatitis and cirrhosis), and progression to hepatocellu-
lar carcinoma, individuals (and groups) with known risk
factors must be monitored on a regular basis to detect
early cancerous lesions. A number of chemopreventive
agents have been examined in HCC by in vitro and in
vivo studies, both in animal models and in humans.
In particular, from some studies, conducted both in
vivo and in vitro, resveratrol emerged as a promising
molecule that inhibits carcinogenesis with a pleiotropic
mode of action [70] affecting cellular proliferation and
growth, apoptosis, inflammation, invasion, angiogenesis
and metastasis [71,72]. This molecule is present in
grapes, berries, peanuts as well as red wine at different
concentrations; in fact, red grapes provide between 0.24
and 1.25 mg of resveratrol per cup whereas boiled pea-
nuts provide between 0.35 and 1.28 mg of resveratrol.
Also red wines contain the most, at 1.92-12.59 mg per
liter. Some studies report that the daily successful
dosage of resveratrol is between 20 and 50 mg [70]. For
this molecule there are multiple effects and action
mechanism; in fact, several investigations indicated that
the resveratrol has anti-HCC actions due to inhibition
of abnormal cell proliferation and apoptosis through cell
cycle regulation [71,72] whereas other studies reported
that it can suppress the growth of HCC cells and
prevent hepatocarcinogenesis by mitigating oxidative
stress [70].
In vitro studies
Since overexpression of COX-2 was demonstrated in
patients with HCC, especially in nontumorous tissue
with cirrhosis and well-differentiated tumorous tissue, in
vitro studies have revealed that both NS-398, a selective
COX-2 inhibitor, and sulindac, an analog of nonsteroi-
dal anti-inflammatory drugs, effectively inhibit growth of
human hepatoma cell lines, which is mediated by a
decreased rate of cell proliferation [73]. Recent evidence
suggested that cyclooxygenase-2 (COX-2)-derived pros-
taglandin PGE(2) and Wnt/beta-catenin signaling path-
ways are implicated in hepatocarcinogenesis and
reported that omega-3 polyunsaturated fatty acids
(PUFA), docosahexaenoic acid (DHA), and eicosapentae-
noic acid (EPA) inhibited HCC growth through simulta-
neously inhibition of COX-2 and beta-catenin [74].
Some studies examined the possible combined effects of
acyclic retinoid (ACR) plus Valproic acid (VPA) in
HepG2 human HCC cell line. In particular, VPA is a
histone deacetylase inhibitor (HDI), induces apoptosis
and cell cycle arrest in cancer cells and enhances the
sensitivity of cancer cells to retinoids. Their combination
synergistically inhibited the growth of HepG2 cells with-
out affecting the growth of normal human hepatocytes
and increased the expression of RARb and p21(CIP1),
while inhibiting the phosphorylation of RXRa.T h i s
combination resulted an effective regimen for the che-
moprevention and chemotherapy of HCC [75]. Finally,
Castello et al. Journal of Translational Medicine 2010, 8:109
http://www.translational-medicine.com/content/8/1/109
Page 6 of 11the combination of 9-cis-retinoic acid (9cRA) plus tras-
tuzumab resulted to inhibit the activation of HER2 and
its downstream signaling pathways, subsequently inhibit-
ing the phosphorylation of RXR alpha and the growth of
HCC cells [76].
In animal models
Chemopreventive agents in preclinical development
stage include S-adenosyl-L-methionine [77], curcumin
[78], a 5a-reductase inhibitor [79], vitamin E [80], vita-
min D [81], and green tea [82], as well as a number of
herbal extracts. Moreover, the preventive effect of flavo-
noids, quercetin or Acacia nilotica bark extract (ANBE)
via oxidant/antioxidant activity was demonstrated on
hepatic cancer in rats [83-85]. Recently several other
molecules with antioxidative properties were evaluated
(for example, Siraitia grosvenorii extract, black tea poly-
phenols, xanthohumol from hops (Humulus lupulus L.))
[86-88]. Also, butyric acid (BA) being a member of his-
tone deacetylase inhibitors (HDAI) has been proposed
as chemiopreventive agent. In fact some studies have
tested the efficacy of tributyrin (TB), a proposed BA
prodrug, on rats treated with the compound during
initial phases of “resistant hepatocyte” model of hepato-
carcinogenesis. TB increased hepatic nuclear histone
H3K9 hyperacetylation specifically in PNL and p21 pro-
tein expression, which could be associated with HDI
effects [89]. In 2008 the antiproliferative effect of gallic
acid was investigated during diethylnitrosamine (DEN)-
inducedHCC) in rats. Gallic acid treatment significantly
attenuated some alterations (i.e. increased levels of
aspartate transaminase, alanine transaminase, alkaline
phosphatase, acid phosphatase, lactate dehydrogenase,
gamma-glutamyltransferase, 5’-nucleotidase, bilirubin,
alpha-fetoprotein, carcinoembryonic antigen) and
decreased the levels of argyophillic nucleolar organizing
regions (AgNORs) and proliferating cell nuclear antigen
(PCNA) [90].
Several studies have investigated the effect of selenium
on different phases of hepatocarcinogenesis using vary-
ing in vivo hepatocarcinogenesis protocols. Selenium is
an essential mineral for both human and animals and
functions as a component of several proteins, termed
selenoproteins (i.e. glutathione peroxidases, thioredoxin
reductates, selenoprotein P etc) [91]. The level of sele-
nium added to the American Institute of Nutrition 93
(AIN-93) diet was 0.15 mg Se/kg diet, with the total
amount estimated to be about 0.18 mg/kg diet, due to
background levels in the other ingredients of the diet
[92]. Several early studies observed that selenium inhib-
ited complete carcinogenesis in the liver. It was also
demonstrated that using a Solt-Farber protocol, 1 and
5 mg/kg selenium administered to rats during the initia-
tion had no effect on the number and volume of hepatic
nodules, but selenium administered during either the
promotion or 6 month progression stages decreased the
volume occupied by the nodules in the liver [93].
Finally, a study in 2010 on lanreotide, a somatostatin
analogue, showed that it inhibits the development of
“foci of altered hepatocytes”, which represent very early
neoplastic changes in rat liver, and decreases hepatocyte
proliferation and inhibition of fibrosis in rats model [94].
In human
In the setting of secondary chemoprevention, literature
data pooling suggests a slight preventive effect of inter-
feron (IFN) on HCC development in patients with
HCV-related cirrhosis. The magnitude of this effect is
low, and the observed benefit might be due to spurious
associations. The preventive effect is limited to sustained
virological responders to IFN [95]. In fact, a-interferon
therapy leads to complete viral eradication in some
long-term responders; its persistence thus depends on
HCV RNA replication [96]. However, IFN reduced the
risk of HCC in HCV-related liver cirrhosis [97] whereas
the HALT-C study showed that long-term therapy with
I F Nd i dn o tr e d u c et h er a t eo fd i s e a s ep r o g r e s s i o ni n
patients with chronic hepatitis C and advanced fibrosis,
with or without cirrhosis [98]. Overall, the best long-
term benefit of IFN is seen almost exclusively in long-
term virologic responders, since no significant differ-
ences between treated patients and untreated patients,
[99]. Annual incidence of HCC in HCV-related cirrhotic
or pre-cirrhotic liver is reported as 4-8%, and IFN-a
treatment is estimated to reduce approximately 50% of
annual incidence of HCC in chronic hepatitis C with
cirrhotic or pre-cirrhotic liver, if SVR rate of approxi-
mately 30% is achieved. Preventive effect of IFN-alpha
on HCC development is considered because of anti-
necroinflammatory effect and suppression of viral repli-
cation. Furthermore, SVR leads to the regression of
histological fibrosis, even in cirrhotic liver [100].
Glycyrrhizin, an aqueous extract of licorice root, was
reported to decrease the risk of HCC in HCV-infected
individuals [101] as well as medicinal ginseng was tested
for HCC-preventive capability among HCV-infected
Japanese patients [102]. A study on vitamin A (retinol)
showed that low levels of retinol were present up to five
years before HCC diagnosis among individuals who
developed this disease [103].
Muto et al randomly assigned 89 HCC patients who
were cancer free following resection or ablation to
receive polyprenoic acid, an acyclic retinoid, and showed
that the recurrence rate was about 50% lower in the
retinoid treated group [104,105].
The role of selenium was investigated also in chemo-
prevention. Several studies have investigated on HCV-
associated HCC patients the selenium (Se) effect, In
Castello et al. Journal of Translational Medicine 2010, 8:109
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b a s e di nC h i n aa n dt h er e m a i n i n gt r i a l sw e r ei nt h e
U S A ,I t a l ya n dI n d i a .T h ef i r s tC h i n at r i a lf o u n dt h a t
selenium supplementation using table salt fortified with
sodium selenite (30-50 mg Se/day) resulted in an almost
50% decrease in the primary liver cancer incidence
[106]. Another study showed that selenite-fortified salt
supplementation reduced the incidence rate of viral
infectious hepatitis [107]. Yu et al [106] reported also a
significant decrease in primary liver cancer among those
receiving selenium yeast compared with controls.
However other epidemiological studies have demon-
strated that higher serum level of other antioxidants do
not seem to correlate with liver cancer prevention. In
fact, in a population-based 11.7-year follow-up study on
mortality rates from cancer in a Japanese population,
h i g h e rs e r u mt o c o p h e r o l( v i t a m i nE )l e v e l sd i dn o tc o r -
relate with reduced risk of mortality from liver cancer
[108]. Moreover, in a 15-year follow-up prospective
study in males, high serum levels of tocopherols did not
reduce the risk of developing HCC [109]. One epide-
miological study has examined the role of dietary vita-
min C in liver cancer etiology. In that prospective study,
Kurahashi et al [110] examined the effect of the con-
sumption of fruit, vegetables, and some antioxidants on
the risk of HCC. Intake of vitamin C in the middle and
highest tertile were found to significantly increase the
risk of developing HCC in smokers, whereas its effect in
non-smokers was not significant.
Conclusions
HCC is unique among cancers occurring mostly in
patients with chronic inflammation and cirrhosis. Its
treatment is challenging since HCC is largely refractory
to chemotherapy and are often silent until local tumor
spread or distant metastasis. Thus, HCC prevention
m i g h tr e p r e s e n tt h eb e s to p p o r t u n i t yt or e d u c et h e
worldwide burden of disease. Although HBV vaccination
will reduce the number of individuals at risk for HCC
development, a tremendous number of people are cur-
rently at elevated risk for HCC due to HCV-correlated
chronic hepatitis and/or cirrhosis. This population with
known risk factors has to be monitored on a regular
basis to detect early cancerous lesions (surveillance and
eventual treatment). Detection and diagnosis of HCC at
an early stage may significantly improve the survival of
patients with this disease. Hence, there is also an
obvious critical need to develop alternative strategies to
prevent HCC development. In fact the HCC chemopre-
vention may be aimed to develop new preventive strate-
gies for reducing inflammation rather than virus
replication. Unfortunately there are limited epidemiolo-
gical data linking increased levels of several antioxidants
with HCC prevention. In fact, human studies do not
provide compelling evidence that consuming higher
amounts of some studied antioxidants would decrease
one’s probability of developing HCC. This suggests that
further studies are needed to develop clinically effective
chemopreventive agents impairing chronic inflammatory
process underlying cancer. Moreover further insight into
the mechanism of chemopreventive agents drugs will
likely to unveil that microenvironment (vasculature, che-
mokine, immuneregulatory cells) is among targets of
chemopreventive agents.
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